BMJ Open

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption

Martin Lund Kårhus,1,2 Andreas Brønden,1 Julie Lyng Forman,3 Anne Haaber,4 Tina Vilsbøll,1,2,5 David Peick Sonne,1,6 Filip Krag Knop1,2,5,7

ABSTRACT

Introduction Bile acid malabsorption (BAM) is a socially debilitating disease characterised by high stool frequency and urgency caused by a spillover of bile acids into the colon. Bile acid sequestrants (BASs) have limited therapeutic effect but represent the only available treatment option. Cases reporting total remission of BAM-related symptoms after treatment with liraglutide, a glucagon-like peptide 1 analogue, prompted us to design a clinical trial investigating the therapeutic effect of this compound in patients with BAM.

Methods and analysis Fifty adult individuals with moderate or severe BAM as assessed by the 75selenium-homotaurocholic acid test (SeHCAT) will, after a run-in period of 10 days with no BAM treatment, be randomised to either treatment with the BAS colesevelam or liraglutide (double blinded) for 6 weeks. Daily symptom diaries and questionnaires will be filled in. Blood and faecal samples will be collected and SeHCAT will be performed at baseline, after week 3 and at end of trial. The primary endpoint is change in daily stool frequency. Secondary endpoints include changes from baseline in self-reported symptoms of BAM, biochemistry, BAM as assessed by SeHCAT and faecal bile acid content and microbial composition.

Ethics and dissemination The study complies with Danish and European Union legislation and is approved by the Danish Medicines Agency, the Regional Scientific Ethics Committee of the Capital Region of Denmark and the Danish Data Protection Agency. The study is monitored by the Capital Region of Denmark’s good clinical practice unit. All results, positive, negative and inconclusive, will be disseminated at national and/or international scientific meetings and in peer-reviewed scientific journals.

Trial registration number EudraCA: 2018-003575-34; Pre-results.

Strengths and limitations of this study

► This is the first randomised clinical trial investigating the glucagon-like peptide 1 receptor agonist liraglutide for the treatment of 75selenium-homotaurocholic acid test (SeHCAT)-verified bile acid malabsorption (BAM).
► The primary endpoint is change in daily stool frequency and the study is powered to establish non-inferiority between liraglutide treatment and the currently recommended treatment for BAM, the bile acid sequestrant colesevelam.
► The study may not be powered to conclude on the secondary endpoints, which include changes from baseline in self-reported symptoms of BAM, biochemistry, BAM as assessed by SeHCAT and faecal bile acid content and microbial composition.

INTRODUCTION

Irritable bowel syndrome (IBS) is the most common bowel disorder with an estimated prevalence in the general population of around 10%.1–3 Patients experience symptoms such as abdominal pain, diarrhoea and changes in the pattern of bowel movements without any apparent evidence of underlying pathology.1 2 In particular, diarrhoea-predominant IBS (IBS-D), which has a reported population prevalence of around 4%,4 5 has debilitating effects and a negative impact on quality of life6 7 and, thus, huge societal and economic implications by occupying healthcare resources and causing loss of productivity.8 A substantial proportion...
(30%) of patients with IBS-D have turned out to suffer from bile acid malabsorption (BAM).8–10

Under normal conditions, bile acids are reabsorbed from the small intestine through a combination of passive absorption and active transport with the latter being predominant in the ileum. Active transport is believed to be the major route for conjugated bile acid uptake, whereas the passive or facilitative absorption along the small intestine may be most significant for unconjugated bile acids.11 12 Only small amounts of bile acids are excreted via faeces. BAM symptoms are caused by spill-over of unabsorbed bile acids from the small intestine to the colon. In the colon, bile acids increase the osmotic gradient and, thus, trigger increased fluid secretion, and they also cause irritation of the colonic mucosa, increased mucosal permeability and mucous secretion and colonic contractions decreasing colonic transit time.13 This causes abdominal pain and diarrhoea, and additional symptoms may include constipation, bloating, faecal urgency and/or faecal incontinence.13 The commonly used test for diagnosis of BAM is the 75selenium-homotaurocholic acid test (SeHCA) that measures the 7-day retention of orally administered 75selenium-labelled bile acid using a gamma camera. Retention of ≥15% is consistent with a normal result, 10%–15% is considered mild BAM, 5%–10% moderate and <5% retention is considered severe BAM.14 The test has high sensitivity and specificity and the radioactive dose is equivalent to a standard chest X-ray.15 16

BAM is typically divided into three types based on the underlying cause: (1) type 1 BAM or secondary BAM encompasses patients with ileal pathology such as Crohn’s disease or ileal resection; (2) in type 2 BAM or idiopathic BAM, no apparent underlying pathology is evident and (3) type 3 BAM includes other underlying causes, for example, coeliac disease.17 It is being debated whether decreased absorption capacity (as indicated by the term BAM) or overproduction of bile due to defective negative feedback of bile acid synthesis is the major contributor to the spillover of bile to the colon.18 Type 1 and 3 BAM are generally managed by treating the underlying conditions. Conventional antidiarrheal pharmacotherapy (codeine and loperamide) seem inefficient in the treatment of BAM.19 Standard treatment of type 2 BAM is orally administered bile acid sequestrants (BASs)15 that work by forming a complex with bile acids preventing the aforementioned effects of free bile acids in the colon. However, BASs are only effective in some patients10 13 and, furthermore, they are associated with gastrointestinal side effects such as dyspepsia, constipation, nausea, borborygmi, flatulence, bloating and abdominal pain in up to 30% of patients.20 The therapeutic limitations and the abovementioned community-based prevalence estimates of BAM (~1.1% of the general population9) combined with the debilitating effects and negative impact on quality of life5 7 underline an unmet need for effective treatment strategies in patients with BAM. Along these lines, the UK National Institute for Health and Care Excellence research recommendations have stressed that in order to address the severe individual and societal implications of BAM, relevant research is crucial to improve the management of the disease.21

Two published cases who experienced total remission of their BAM symptoms after treatment with the glucagon-like peptide 1 receptor (GLP-1R) agonist (GLP-1RA), liraglutide (initiated due to overweight and type 2 diabetes),25 made us speculate whether patients with BAM may benefit from liraglutide treatment. Both cases experienced a relapse of symptoms when treatment was paused and renewed remission after reinitiating liraglutide treatment uptitrated to 1.8 mg/day. In addition to the glucose-lowering and satiety-promoting effects of GLP-1, it is well known that this gut hormone (secreted from enteroendocrine L cells) reduces upper gastrointestinal motility.23 24 Interestingly, treatment with liraglutide (for diabetes (1.8 mg/day)21 and obesity (3 mg/day),25 26 respectively) was recently shown to be associated with the formation of gallstones,26 and, thus, potentially to interact with the enterohepatic circulation of bile acids. In line with this notion, the GLP-1RA, exenatide has been reported to reduce gallbladder emptying in healthy subjects27 and liraglutide was recently shown to delay gallbladder refilling.28 Also, liraglutide has been shown to inhibit small intestinal motility, flow and transit time.24 29

The pathophysiology of BAM combined with evidence suggesting that the effects of GLP-1R activation may lead to reductions in postprandial gallbladder emptying, release of bile into the small intestine and small intestinal flow and transit time could result in increased reabsorption of bile acids, thereby alleviating spillover of bile to the colon in patients with BAM. Furthermore, a greater GLP-1-induced absorption of bile acids in the small intestine may increase the activation of the nuclear bile acid receptor farnesoid X receptor (FXR), and thereby result in FXR-dependent production of small intestinal fibroblast growth factor 19 (FGF19) known to reduce bile acid synthesis.30 31 In line with this notion, low circulating FGF19 concentrations have been observed in patients with BAM.18 Despite the seemingly fit between BAM pathophysiology and the pharmacodynamics of liraglutide, treatment with liraglutide (or other GLP-1RA) has so far not been investigated for the treatment of BAM. Therefore, we have initiated the treatment of bile acid malabsorption with liraglutide (BAM-LIRA) trial.

Hypothesis

We hypothesise that liraglutide-induced activation of the GLP-1R will reduce the exposure of colonic mucosa to bile acids (by the mechanisms alluded to above) and translate into amelioration or improvement in BAM symptoms in patients with BAM to the same extent as conventional BAS treatment (non-inferiority).

Objectives

The overall objective of the present study is to provide proof of concept that treatment with the subcutaneously administered GLP-1RA, liraglutide (Victoza), is
Box 1 Endpoints

| Primary endpoint                  |
|----------------------------------|
| ► Proportion of patients experiencing ≥25% reduction in stool frequency at the end of the 6-week intervention period, with a 15% non-inferiority margin between patients with bile acid malabsorption (BAM) randomised to double-blinded treatment with liraglutide and colesevelam, respectively. |

| Secondary endpoints              |
|----------------------------------|
| ► Proportion of patients experiencing remission of BAM-related diarrhoea (≤2 formed or semifomed stools per day). |
| ► Symptomatic relief of BAM symptoms as assessed by questionnaires filled out once a week. |
| ► Proportion of patients tolerating treatment (ie, maintaining treatment throughout the 6-week treatment period) and not tolerating treatment, respectively. |
| ► Change in health-related quality of life score as assessed by questionnaires filled out every third week. |
| ► Change in percent retention of bile acid (as assessed by 75Selenium-homotaurocholic acid test (SeHCA T) from baseline (of note, SeHCAT results represent exploratory secondary endpoints as colesevelam treatment—in contrast to liraglutide treatment—is expected to reduce retention of bile acids). |
| ► Fasting serum/plasma concentrations of total bile acids, fractionated bile acids, low-density lipoprotein, high-density lipoprotein, very low-density lipoprotein and total cholesterol, triglycerides, free fatty acids, 7α-hydroxy-4-cholesten-3-one (named C4, a marker of bile acid synthesis), fibroblast growth factor 19, glucose, glycated haemoglobin A1C, insulin, C peptide and glucagon. |
| ► Faecal content of bile acids and microbiota composition will be evaluated as exploratory secondary endpoints. |

Box 2 Eligibility criteria

| Inclusion criteria              |
|----------------------------------|
| ► Caucasian ethnicity. |
| ► 75Selenium-homotaurocholic acid test-verified moderate or severe bile acid malabsorption with 7-day retentions of 5%–10% and <5%, respectively. |
| ► Normal haemoglobin (for men 133.63–169.05 g/L; for women 117.53–152.95 g/L). |
| ► Age≥18 years and <75 years. |
| ► Informed and written consent. |
| ► Body mass index >18.5 kg/m² and <40 kg/m². |
| ► Glycated haemoglobin A1C<48 mmol/mol (6.5%). |

| Exclusion criteria              |
|----------------------------------|
| ► History of/ present hepatobiliary disorder (except for simple non-alcoholic steatosis) and/or alanine aminotransferase and/or serum aspartate aminotransferase >3 times upper limit of normal). |
| ► Gastrointestinal disease (except for bile acid malabsorption), previous intestinal resection or previous major intra-abdominal surgery. |
| ► Diabetes mellitus. |
| ► Nephropathy with estimated glomerular filtration rate <60 mL/min/1.73 m². |
| ► Treatment with medicine that cannot be paused for 12 hours. |
| ► Hypothyroidism or hyperthyroidism, if not well regulated. |
| ► Treatment with oral anticoagulants. |
| ► Active or recent malignant disease. |
| ► Any treatment or condition requiring acute or subacute medical or surgical intervention. |
| ► Pregnancy (tested before entering the study), breast feeding or intention to become pregnant. |
| ► Female of childbearing potential not using adequate contraceptive methods including intrauterine device, birth control pills, sexual abstinence or living in a relationship with a sterile partner. |
| ► Known or suspected hypersensitivity to trial products or related products. |
| ► Any condition considered incompatible with trial participation by the investigators. |

as efficacious (as assessed by symptom relief, that is, response to treatment) and safe (as assessed by adverse effects and standard biochemistry) as treatment with the orally administered BAS colesevelam (Cholestagel) in the management of BAM and that it improves bile acid reabsorption (as assessed by SeHCAT) in these patients. The primary endpoint is proportion of patients experiencing response to treatment (ie, ≥25% reduction in stool frequency) at the end of the 6-week intervention period, with a 15% non-inferiority margin between patients with BAM randomised to double-blinded treatment with liraglutide and colesevelam, respectively. If non-inferiority is established, superiority will be evaluated. A range of secondary endpoints (see below) will also be evaluated (box 1).

Trial design

The BAM-LIRA trial is an investigator-initiated 6-week proof-of-concept study. It is designed as a randomised double-blinded double-dummy parallel-group non-inferiority study.

METHODS

Fifty non-diabetic patients with SeHCAT-verified moderate (5%–10% bile acid retention) or severe BAM (≤5% retention) will be recruited. Participants will be randomised 1:1 to receive double-blinded (double dummy) subcutaneous liraglutide or oral colesevelam for 6 weeks after a 10-day washout period of any existing BAM treatment.

Randomisation

The randomisation of colesevelam and colesevelam placebo will be performed by the central pharmacy of the Capital Region of Denmark, using the website randomization.com and will be matched with liraglutide and liraglutide placebo by a study-independent person with no other involvement in the study.

Recruitment

Study participants will be recruited from gastroenterology outpatient clinics and nuclear medical departments performing SeHCAT procedures in the Capital Region of Denmark as well as from private gastroenterology clinics. Potential study participants will be asked if a medical doctor may contact them and inform them about the project. Participants will be included according to specific inclusion criteria (box 2) including severe or...
moderate BAM, normal haemoglobin A1c and informed consent (written and verbal), and exclusion criteria (box 2) including gastrointestinal diseases other than BAM and women of childbearing potential not using efficient contraception.

Procedures and visits

After screening for eligibility (boxes 2 and 3), participants will enter a run-in period of 10 days without any treatment for their BAM. Prior to initiation of study drugs, participants will be randomised 1:1 to 6 weeks of treatment with (1) once-daily subcutaneous dosing of the liraglutide (weekly up titration by 0.6 mg, from 0.6 mg to 1.8 mg) and two times per day oral dosing of colesevelam placebo or (2) two times per day oral dosing of the BAS colesevelam (1875 mg) and one daily subcutaneous dose of liraglutide placebo (the same up titration regimen as for liraglutide).

Faecal and blood samples will be collected and SeHCATs will be performed at randomisation, at week 3 and at the end of study (figure 1). Daily symptom diaries based on the Bristol Stool-form Scale will be used to record stool frequency and consistency throughout the run-in period and the intervention period. Patients will be asked at visits and informed to record any adverse events in their symptom diaries. Questionnaires regarding symptoms of BAM and quality of life will be answered every week and every third week, respectively. Data will be stored in a digital case report form using the system Research Electronic Data Capture (REDCap) (Vanderbilt University, Nashville, Tennessee, USA). In case of emergencies, unblinding will be made on an individual basis and will not affect other participants.

The study was initiated in March 2019 and last patient last visit is expected in first quarter of 2021.

Patient and public involvement

No patients or the public were involved in the development of this protocol.

Intervention

Liraglutide (Victoza) and liraglutide placebo are supplied by Novo Nordisk A/S (Bagster, Denmark), the producer of Victoza. The pens for injection contain 18 mg of the GLP-1RA liraglutide in 3 mL sterile water with disodium phosphate and propylene glycol and phenol for conservation (pH 8.15). The placebo pens are indistinguishable from the Victoza pens and contain the same except from the liraglutide constituent. Liraglutide placebo is administered in the same way and volume as liraglutide. The placebo pens will be specially prepared for this study and will be used in this study only. The BAS colesevelam (Cholestagel) is supplied in pill form containing 625 mg of colesevelam. The colesevelam and the colesevelam placebo will be bought and formulated into identical capsules manufactured by the central pharmacy of the Capital Region of Denmark to ensure blinding.

Drug ordering and storage

The liraglutide and liraglutide placebo pens will be delivered in separate boxes and will be stored securely in a refrigerator at 2–8°C (distant from any freezer compartment). The cap will be kept on the pen in order to protect from light. Pens that are in use can be kept at temperatures 2–30°C for 1 month. Participants will be instructed to keep the pens away from direct sunlight to refrain using the pens if the injection fluid is unclear or coloured. The capsules containing colesevelam and colesevelam placebo will be delivered from the Central Pharmacy of the Capital Region of Denmark and will be kept dry and stored according to label.

Drug accountability

One investigator will be responsible for drug accountability. For each patient treated, the batch number of pens and containers will be documented. Patients will be asked to return pens and containers after use. After verification of drug accountability, proper destruction of pens, containers and capsules will be ensured. During the study, the participants will be informed to register drug use daily in order to document administration of drugs and to ensure compliance.

Sample size

Sample size has been calculated based on the primary binary outcome (response/no response): proportion of patients experiencing response to treatment (ie, ≥25% reduction in stool frequency). An online calculator designed for binary outcomes in parallel group non-inferiority trials has been used. P values<0.05 will be accepted as statistically significant, that is, level of significance (2α)=5%. The power of the study (1–β) is set to 80%, with β=20%. Following BAS treatment, approximately 80% of patients with BAM have positive effects on bowel symptoms. We assume that the response following liraglutide treatment is 90%, and we have chosen 15% as the non-inferiority limit, resulting in a sample size required per group of 25. Thus, if there is a true difference in favour of liraglutide treatment, then 50 patients are required to be 80% sure that the upper limit of a one-sided 95% CI (or equivalently a 90% two-sided CI) will exclude a difference in favour of the standard
group of more than 15%. Dropouts will be replaced. The reason for dropouts will be documented and reported.

**Data analysis**

Continuous data will be presented by descriptive statistics with the number of observations, mean, SD, minimum, median and maximum. Substantially skewed data (ie, with mean-SD or otherwise implausible normal range) will be log transformed. Categorical data will be summarised with counts and percentages. Data from patients screened, but not randomised, will not be presented in any tables or listings.

**Primary endpoint**

A risk difference with 95% CIs will be calculated to compare the proportions of patients with positive response.
(ie, ≥25% reduction in stool frequency) between the two treatment groups. If the CI excludes a more than 15% difference in favour of standard treatment, non-inferiority will be concluded. If non-inferiority is concluded, testing for superiority will be made.

Secondary endpoints

Total symptoms score, quality of life scores and biomarker values will be analysed using a constrained linear mixed model with inherent baseline adjustment and with an unstructured covariance pattern. Changes from baseline within and between groups will be reported with 95% CIs. Proportions of patients tolerating the treatment and proportion of patients experiencing remission of BAM-related diarrhoea within each group will be reported with exact binomial CIs and compared between groups using risk differences and Fisher’s exact test. Changes in SeHCAT estimates will be analysed using a linear mixed model with an unstructured covariance pattern. Changes from baseline will be reported with 95% CIs.

Handling of missing data

In the primary analysis, all missing outcomes will be considered as a negative outcome (non-responders), that is, ≤25% reduction in stool frequency. Best-case and worst-case scenarios considering all missing data in a group as either positive or negative outcomes will be used for sensitivity analyses. Missing data for binary secondary outcomes will be handled similarly to the primary endpoint data. Missing data for continuous outcomes will be handled implicitly by maximum likelihood estimation in the constrained linear mixed models.

Adjustment for multiple testing

P values from the secondary analyses will be adjusted for multiple testing using the method of Benjamini and Hochberg controlling for false discovery rate.

Side effects, risks and disadvantages for participants

The summary of product characteristics (SPC) for Cholestagel lists potential side effects and risks related to treatment with this drug. Side effects comprise nausea, vomiting, dyspepsia, abdominal pain, obstipation, flatulence and/or diarrhoea. Cholestagel constitutes a standard treatment of BAM and we do not expect any serious adverse events or persistent consequences for the participants. The pause of BAM treatment during the run-in period may cause BAM symptoms identical to the ones experienced before initiation of BAM treatment. The SPC for Victoza lists diarrhoea, nausea, vomiting and constipation as very common side effects. The SPCs of Cholestagel and Victoza will be used as a reference to evaluate if any side effect was expected or not. According to the half-life for liraglutide and the poor absorption of colesevelam, it is considered safe that women of childbearing potential will be told to continue their contraception for a month after the study is finished. We will be monitoring the patients closely during the intervention and we expect only few and mild-to-moderate side effects, if any. Adverse events including serious adverse events will be documented and reported according to Danish and European Union legislation. The maximum amount of blood collected during the entire trial will not exceed 100 mL for each trial participant.

Study approval

The BAM-LIRA study is approved by the Danish Medicines Agency, the Regional Health Research Ethics Committee of the Capital Region of Denmark and the Danish Data Protection Agency and registered at the European Union Drug Regulating Authorities Clinical Trials (EudraCT) (2018-003575-34). The study will be conducted in accordance with good clinical practice as outlined in the Declaration of Helsinki and the International Conference on Harmonisation-Good Clinical Practise (ICH-GCP) guidelines and monitored by the Capital Region of Denmark’s Good Clinical Practice Unit.

Ethics and dissemination

BAM is a common disease with symptoms that can be socially debilitating and often are considered taboo, making it difficult for many patients to maintain a normal work and social life. Furthermore, costs covering diagnostics and treatment are high and the disease bears the blame for many lost working days and lack of productivity. Both colesevelam and liraglutide are well known and commonly used medications. They are safe and we only expect mild-to-moderate and, in most cases, temporary side effects, if any. Therefore, we find the planned intervention (including 6 weeks of intervention) proportional to the potential positive results that the study may provide. Data from the study will be processed and results will be presented in one or more manuscripts for publication in scientific peer-reviewed journals. Also, the results of the study will be submitted for presentation at relevant national and/or international scientific meetings/conferences. Inconclusive, negative and positive results will be published and presented in accordance with Danish law concerning processing of personal data. All authors must fulfill criteria for authorship according to International Committee of Medical Journal Editors. All data from the study will be owned by the investigators.

Author affiliations

1 Center for Clinical Metabolic Research, Gentofte University Hospital, University of Copenhagen, Hellerup, Denmark
2 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
3 Section of Biostatistics, Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
4 Mavespecialisten, Charlottenlund, Denmark
5 Steno Diabetes Center Copenhagen, Gentofte, Denmark
6 Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
7 Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Correction notice This article has been corrected since it was first published. Middle name for the author ‘Filip Krag Knop’ has been corrected.
Contributors MLK and FKKK wrote the manuscript. AB, JLF, AH, TV and DPS reviewed and edited the manuscript.

Funding The study was supported by Novo Nordisk A/S which supplied the liraglutide and matching placebo and funded by an unrestricted grant (NNF17OC0029710) and by the Foundation for the Advancement of Medical Science under The A.P. Møller and Chastine Mc-Kinney Møller Foundation (19–L-0002). The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

Competing interests TV has served on scientific advisory panels, been part of speakers’ bureaus for, served as a consultant to and/or received research support from Agena, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, Mundipharma, MSD/Merck, Novo Nordisk, Sanofi and Sun Pharmaceuticals. FKKK has served on scientific advisory panels, has been part of speaker’s bureaus for, served as a consultant to and/or received research support from Agena, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi and Zealand Pharma, and is a minority shareholder in Antag Therapeutics ApS.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Filip Krag Knop http://orcid.org/0000-0002-2495-5034

REFERENCES

1 National Institute for Health and Clinical Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK), 2008. https://www.nice.org.uk/guidance/cg61

2 Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21.

3 Spiller RC. Irritable bowel syndrome. Br Med Bull 2004;72:15–29.

4 Chang L, Lembo A, Sultian S. American gastroenterological association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014;147:1149–72.

5 Halder SLS, Locke GR, Schlecld CD, et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology 2007;133:799–807.

6 Andrae DA, Patrick DL, Drossman DA, et al. Evaluation of the irritable bowel syndrome quality of life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes 2013;11:208.

7 Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from logic (longitudinal outcomes study of gastrointestinal symptoms in Canada), a naturalistic study. Clin Ther 2006;28:1726–35.

8 National Institute for Health and Clinical Excellence (NICE). SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn’s disease without ileal resection. London: National Institute for Health and Clinical Excellence (NICE), 2012. https://www.nice.org.uk/guidance/dg7

9 Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2015;42:3–11.

10 Wedlake L, A’Herin R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009;30:707–17.

11 Krag E, Phillips SF. Active and passive bile acid absorption in man. perfusion studies of the ileum and jejunum. J Clin Invest 1974;53:1686–94.

12 Schiff ER, Small NC, Dietschy JM. Characterization of the kinetics of the passive and active transport mechanisms for bile acid absorption in the small intestine and colon of the rat. J Clin Invest 1972;51:1351–62.

13 Wilcox C, Turner J, Green J. Systematic review: the management of chronic diarrhoea due to bile acid malabsorption. Alliment Pharmacol Ther 2014;39:923–39.

14 Vijayvargiya P, Camilleri M, Shin A, et al. Methods for diagnosis of bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol 2013;11:1232–9.

15 Notghi A, O’Brien J, Low CS, et al. Measuring SeHCAT retention: a technical note. Nucl Med Commun 2011;32:960–6.

16 Sciarretta G, Vicini G, Fagioli G, et al. Use of 23-selena-25-homocholyltaurine to detect bile acid malabsorption in patients with ileal dysfunction or diarrhea. Gastroenterology 1986;91:1–9.

17 Pattni S, Walters JRF. Recent advances in the understanding of bile acid malabsorption. Br Med Bull 2009;92:79–93.

18 Walters JRF, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhoea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7:1189–94.

19 Smith MJ, Cherian P, Raju GS, et al. Bile acid malabsorption in persistent diarrhoea. J R Col Physicians Lond 2000;34:448–51.

20 Wildt S, Norby Rasmussen S, Lysgard Madsen J, et al. Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol 2003;38:826–30.

21 Marso SP, Daniels GH, Brown-Brandes K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–22.

22 Kårhus ML, Branden A, Roder ME, et al. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide. Gastroenterology 2019;157:869–71.

23 Hellström PM, Näslund E, Edholm T, et al. Glp-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008;20:649–59.

24 Hatai H, Khemani D, Eckert D, et al. Encistion of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastroenterol Hepatol 2017;2:890–9.

25 Wadden TA, Hollandar P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the scale maintenance randomized study. Int J Obes (2015;39:187.

26 Pi-Sunyer X, Asstrup A, Fujikoa K, et al. A randomized, controlled trial of 3.0 Mg of liraglutide in weight management. N Engl J Med 2015;373:11–22.

27 Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept 2012;179:77–83.

28 Nexoee-Larsen CC, Sørensen PH, Hausner H, et al. Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab 2018;20:2557–64.

29 Nakatani Y, Maeda M, Matsumura M, et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab 2017;43:430–7.

30 Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascode for the suppression of bile acid biosynthesis. Dev Genes Evol 2003;17:1581–91.

31 Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217–25.

32 Li Y, Lu L-Q. Therapeutic roles of bile acid signaling in chronic liver diseases. J Clin Transl Hepatol 2018;6:1–6.

33 Borghede MK, Schlüter JM, Agholtt JS, et al, Bile acid malabsorption investigated by selenium-75-homocholic acid taurine ([75]SeHCA) scans: causes and treatment responses to cholestyramine in 298 patients with chronic watery diarrhea. Eur J Intern Med 2011;22:137–40.

34 Walters JRF, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010;3:549–57.

35 European medicines agency science medicines health. Cholestagel(R) summary of product characteristics, 2020. Available: http://www.ema.europa.eu/en/medicines/human/EPAR/cholestagel

36 European medicines agency science medicines health. Victoza(R) Summary of product characteristics, 2017. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&mid=WCOb01ac05800112d4